Newly combined Tobira/Regado to receive $22mm investment; finalized at $27mm
Executive Summary
Tobira Therapeutics Inc. (hepatic and infectious diseases), which is reverse merging with Regado Biosciences Inc. to go public, plans to raise $22mm from Tobira's investors including Domain Associates, Novo Ventures, Frazier Healthcare, Montreux Equity Partners, and Canaan Partners. The financing is expected to occur before or concurrent with the closing of the Regado deal. The money will fund the completion of cenicriviroc's Phase IIb trial in nonalcoholic steatohepatitis (NASH) and liver fibrosis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice